United States Inhalation Systems Market Forecasts, 2018-2024 with a Market Snapshot of Sleep Apnea, Anesthesia & Pulmonary Medicine - ResearchAndMarkets.com

The "US
Inhalation Systems Market Forecast up to 2024" report has been
added to ResearchAndMarkets.com's offering.

The US Inhalation Systems Market is estimated to witness a CAGR of 5.8%
during the forecast period 2018-2024. The US market is analyzed based on
three segments - products, applications, and end-users.

The emergence of inhaled drug therapy has been a boon for patients with
respiratory conditions such as COPD and asthma because of its painless
and flexible administration when compared to injections. There are
various kinds of inhalation systems available in the market, and these
include inhalers and nebulizers. The two most commonly widespread
respiratory diseases are asthma and COPD. According to WHO, around 235
million people are currently suffering from asthma, and it is very
common in children.

Chronic respiratory diseases such as asthma and COPD are responsible for
substantial financial and health burden in the US, and in 2015, 6.7%
deaths in the US were due to chronic respiratory diseases. Chronic
obstructive pulmonary disease is the third leading cause of death across
the globe, accounting for approximately 3 million deaths in 2016. State
of West Virginia has the highest prevalence of COPD, and around 12% of
the population are diagnosed with COPD.

The US inhalation systems market is driven by an upsurge in the
prevalence of respiratory diseases, increasing geriatric population, and
favorable reimbursement. However, side effects allied with the drug
inhalation and unattainability of single effective inhaler device that
can treat many disease conditions may slow down the growth of the market
in the US.

Market Analysis:

Product Analysis:

The US inhalation systems market, by product, is segmented into inhalers
and nebulizers. The market by inhalers type is further segmented into
dry powder inhalers and metered dose inhalers. The market by nebulizers
is segmented into ultrasonic nebulizer, pneumatic nebulizer, and mesh
nebulizer.

Inhalers occupied a major market share in 2017 and nebulizers segment is
anticipated to grow at a high CAGR during the forecast period. The
extensive usage of inhalers in the treatment of various respiratory
illness such as asthma, chronic obstructive pulmonary disorder, and
others makes the segment the major shareholder.

Application Analysis:

The US inhalation systems market, by application, is segmented into
asthma, chronic obstructive pulmonary disease (COPD), and others. Asthma
occupied a major market share in 2017 and COPD is expected to grow at
the highest rate in the next five years.

End-users Analysis: The US inhalation systems market by
end-users is segmented into hospitals, ambulatory care centers, and home
care centers. Hospitals occupied a major market share in 2017, and home
care segment is expected to grow during the forecast period due to ease
in the usage of modern products, less homecare cost, and the
obtainability of reimbursement.

Competitive Analysis:

There is an increase in approvals in recent years due to the popularity
of the systems and also drug companies are launching new inhalation
systems and collaborating with other vendors to develop innovative
devices in the market. For instance, in February 2017, FDA approved tw-
products developed by Teva Pharmaceutical Industries Ltd., ArmonAir
RespiClick and AirDu- RespiClick, to treat adolescent and adult patients
with asthma.

In October 2017, FDA approved new inhalation device, named TD-300/A
developed by United Therapeutics Corporation, for use with Tyvas-
Inhalation Solution. The first triple combination inhaler named Trimbow
launched for COPD in August 2017 and in February 2018, Teva
Pharmaceutical Industries Ltd. announced the commercial availability of
QVAR RediHaler Inhalation Aerosol to patients in the US.

Key Topics Covered:

1 Industry Outlook

1.1 Industry overview

1.2 Industry Trends

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition

3.2 Advantages of inhalation systems

3.3 Limitations associated with inhalation systems

3.4 Segmented Addressable Market (SAM)

3.5 Trends of the US inhalation systems market

3.6 Related Markets

3.6.1 Sleep Apnea

3.6.2 Anesthesia

3.6.3 Pulmonary Medicine

4 Market Outlook

4.1 History of Inhalation systems

4.2 Market segmentation

4.3 PEST Analysis

4.4 Porter 5 Forces

5 Market Characteristics

5.1 DRO - US Inhalation Systems Market Dynamics

5.1.1 Drivers

5.1.1.1 Rising prevalence's of respiratory diseases

5.1.1.2 Favorable reimbursement

5.1.1.3 Increasing geriatric population

5.1.2 Opportunities

5.1.2.1 Advancement in technology

5.1.2.2 Upsurge in the demand for home-care therapeutic devices

5.1.3 Restraints

5.1.3.1 Side effects allied with drug inhalation

5.1.3.2 Unattainability of solo effective inhaler device that can treat
many disease conditions

5.2 DRO - Impact Analysis

5.3 Key Stakeholders

6 By Products: Market Size and Analysis

6.1 Overview

6.2 Inhalers

6.2.1 Dry powder inhalers

6.2.2 Metered dose inhaler

6.2.3 Soft mist inhaler

6.3 Nebulizers

6.3.1 Ultrasonic Nebulizers

6.3.2 Pneumatic/jet Nebulizers

6.3.3 Mesh Nebulizers

7 By Applications: Market Size and Analysis

7.1 Overview

7.2 Asthma

7.3 Chronic obstructive pulmonary disease (COPD)

7.4 Others

8 By End-Users: Market Size and Analysis

8.1 Overview

8.2 Hospitals

8.3 Ambulatory care centers

8.4 Home Care

9 Regions: Market Size and Analysis

9.1 Overview

9.2 United States

10 Competitive Landscape

10.1 Overview

11 Vendor Profiles

• 3M
• Agilent Technologies Inc.
• AptarGroup Inc.
• AstraZeneca PLC
• Becton Dickinson
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Inspiro Medical Ltd.
• Monaghan Medical Corporation
• Omron Corp.
• PARI GmbH
• Philips Healthcare
• Teleflex Incorporated
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/6ql7qb/united_states?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005400/en/